Hemorrhagic Brain Injury Repair with Human Cord Blood

用人脐带血修复出血性脑损伤

• 批准号: 6992921
• 负责人: WALTER C LOW
• 金额: $ 15.87万
• 依托单位: SANERON CCEL THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-20 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6992921
• 关键词: astrocytes; cell differentiation; cell population study; cerebral hemorrhage; clinical research; collagenase; cord blood; cyclosporines; human tissue; immunocytochemistry; laboratory rat; neurons; neuropsychological tests; nonhuman therapy evaluation; oligodendroglia; stem cell transplantation; stroke therapy; therapy design /development

DESCRIPTION (provided by applicant): Human umbilical cord blood (hUCB) is a rich source of stem cells that exhibit multipotent properties. Previous studies have shown that hUCB cells can differentiate into neural cells under the appropriate environment conditions. SANERON CCEL, Inc. is focusing on the use of hUCB as a therapeutic approach for treating a variety of neurological disorders. In this Phase I STTR study we will evaluate the efficacy of using hUCB in treating experimental hemorrhagic brain injury. Intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality. Patients who survive are often left severely disabled, and the costs for caring for these individuals are substantial. Improvements in function for patients with ICH would add significantly to their quality of life and reduce the cost for care. We will evaluate the effects of administering hUCB intravenously into rats with collagenase-induced ICH of the striatum. hUCB will be given at various time periods after the induction of the hemorrhage. Animals will then be evaluated periodically to assess their neurological status over time. Comparisons will be made between hUCB treated animals and those receiving other types of sham therapy. After the neurological assessments, brain tissue from each animal will be studied histologically to determine whether hUCB cells differentiated into neural cells within the environment of the hemorrhagic brain. The results from this study will provide information on whether hUCB can be used as a therapy for treating hemorrhagic brain injury.

描述（由申请人提供）：人脐带血（hUCB）是一种丰富的干细胞来源，具有多能特性。以往的研究表明，hUCB细胞可以在适当的环境条件下分化为神经细胞。SANERON CCEL，Inc.是集中在使用hUCB作为治疗各种神经系统疾病的治疗方法。在该I期STTR研究中，我们将评估使用hUCB治疗实验性出血性脑损伤的功效。 脑出血（ICH）是发病率和死亡率的主要原因。存活下来的病人往往严重残疾，照顾这些人的费用很高。 ICH患者功能的改善将显著提高他们的生活质量并降低护理成本。我们将评估静脉内施用hUCB到患有胶原酶诱导的纹状体ICH的大鼠中的效果。hUCB将在诱导出血后的不同时间段给予。然后定期评价动物，以评估其随时间推移的神经系统状态。将在hUCB处理的动物和接受其他类型的假治疗的动物之间进行比较。神经学评估后，将对每只动物的脑组织进行组织学研究，以确定hUCB细胞是否在出血性脑的环境中分化为神经细胞。本研究的结果将提供有关hUCB是否可用作治疗出血性脑损伤的疗法的信息。